Ken Griffin Mannkind Corp Put Options Transaction History

Citadel Advisors LLC

  • $550 Billion
  • Q2 2025

Put Options

12 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$3.71 - $5.04 $125,398 - $170,352
-33,800 Reduced 30.23%
78,000 $291,000
Q1 2025

May 15, 2025
SELL
$4.92 - $6.6 $769,488 - $1.03 Million
-156,400 Reduced 58.31%
111,800 $562,000
Q4 2024

Feb 14, 2025
BUY
$5.93 - $7.44 $521,840 - $654,720
88,000 Added 48.83%
268,200 $1.72 Million
Q3 2024

Nov 14, 2024
SELL
$5.01 - $6.7 $337,674 - $451,580
-67,400 Reduced 27.22%
180,200 $1.13 Million
Q2 2024

Aug 14, 2024
BUY
$4.05 - $5.43 $163,620 - $219,372
40,400 Added 19.5%
247,600 $1.29 Million
Q1 2024

May 15, 2024
BUY
$3.25 - $5.27 $97,825 - $158,627
30,100 Added 17.0%
207,200 $938,000
Q4 2023

Feb 14, 2024
BUY
$3.34 - $4.29 $339,010 - $435,435
101,500 Added 134.26%
177,100 $644,000
Q3 2023

Nov 14, 2023
BUY
$3.91 - $5.45 $30,107 - $41,965
7,700 Added 11.34%
75,600 $312,000
Q2 2023

Aug 14, 2023
BUY
$3.72 - $4.79 $4,092 - $5,269
1,100 Added 1.65%
67,900 $276,000
Q1 2023

May 15, 2023
SELL
$3.95 - $5.63 $396,185 - $564,689
-100,300 Reduced 60.02%
66,800 $273,000
Q4 2022

Feb 14, 2023
SELL
$3.02 - $5.37 $126,236 - $224,466
-41,800 Reduced 20.01%
167,100 $880,000
Q3 2022

Nov 14, 2022
SELL
$2.99 - $4.35 $813,878 - $1.18 Million
-272,200 Reduced 56.58%
208,900 $646,000

Others Institutions Holding MNKD

# of Institutions
248
Shares Held
161M
Call Options Held
1.24M
Put Options Held
179K
View Full List

About MANNKIND CORP

MNKD Quotes by TradingView
  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $942M
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email